Additionally, the PIONEER AF-PCI trial reported positive results with similar rivaroxaban dosing in individuals with AF that underwent percutaneous coronary intervention (PCI) comparing 15 mg rivaroxaban once daily, 2.5 mg rivaroxaban twice daily both in addition to a P2Y12 inhibitor, compared to VKA and DAPT [7]. Here, P2RY12 is linked to atrial fibrillation.